Stock UK0DPBLSEHealthcareValue Trap

Bavarian Nordic A/S(0DPB) Stock Analysis | Healthcare

DKK --+0.00%

Reward42Moderate

Risk35Moderate

50%Data

Strong 24% profit margin · Revenue growing 23% YoY

DKK —+0.00 (+0.00%) Previous close · LSE

Market cap 12.22Bn

Reward Ratingⓘ42 Moderate reward assessment · 50% data coverage

Bottom 10% of stocksView factors

Risk Ratingⓘ35 Moderate risk assessment

Risk factors availableUnlock details

Earnings & dividend markersEarnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Bavarian Nordic A/S?

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines.

AI Brief Pro

The brief on Bavarian Nordic A/S

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Bavarian Nordic A/S?

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. The company is listed on the LSE in UK, operating in the Healthcare sector, with a market capitalisation of 12.22B.